Full video transcriptClick to expand
Auto-generated transcript of @b.louden06's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Some of you have asked me about C-Max or other BDNF increasing compounds causing hair loss.
- 0:04It's just not going to happen.
- 0:07There are some studies that show that when you directly apply BDNF to hair follicles,
- 0:12it slows their growth phase.
- 0:14But it's just that it's slowing the growth phase.
- 0:16So it's not actually causing loss of hair.
- 0:19But also you're not going to get that concentrated levels of BDNF directly to your hair follicles.
- 0:24So you really don't have to worry about it at all.
Semax and neuroplasticity: what TikTok gets wrong about brain peptides
Quick answer
Semax is an ACTH(4-7) analogue that has been shown in animal studies to upregulate BDNF expression in the central nervous system, but human pharmacokinetic data on its peripheral distribution, including to scalp tissue, is not established in published literature. The creator's claim that systemic semax use cannot produce follicle-level BDNF concentrations sufficient to affect hair cycling is mechanistically plausible but unverified. No peer-reviewed human trials specifically examining semax and hair follicle biology have been published in indexed English-language journals.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Semax and neuroplasticity: what TikTok gets wrong about brain peptides, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Semax and neuroplasticity: what TikTok gets wrong about brain peptides should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Semax and neuroplasticity: what TikTok gets wrong about brain peptides" from B.Louden. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semax is an ACTH(4-7) analogue that has been shown in animal studies to upregulate BDNF expression in the central nervous system, but human pharmacokinetic data on its peripheral distribution, including to scalp tissue, is not established in published literature.
The reason this review is not generic is the source wording and the canonical claim label "peptides neuroplasticity nootropics brain iq money semax." In this clip, the useful excerpt is: "Some of you have asked me about C-Max or other BDNF increasing compounds causing hair loss." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Functional Connectomic Approach to Studying Selank and Semax Effects (2020), Effects of Semax on the Default Mode Network of the Brain (2018), and Therapeutic Peptides: Applications, Challenges, and Future Directions (2026), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semax is an ACTH(4-7) analogue that has been shown in animal studies to upregulate BDNF expression in the central nervous system, but human pharmacokinetic data on its peripheral distribution, including to scalp tissue, is not established in published literature.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semax is an ACTH(4-7) analogue that has been shown in animal studies to upregulate BDNF expression in the central nervous system, but human pharmacokinetic data on its peripheral distribution, including to scalp tissue, is not established in published literature. The creator's claim that systemic semax use cannot produce follicle-level BDNF concentrations sufficient to affect hair cycling is mechanistically plausible but unverified. No peer-reviewed human trials specifically examining semax and hair follicle biology have been published in indexed English-language journals.
- BDNF does interact with hair follicle biology: Botchkarev et al. (1999) showed TrkB receptors are expressed in follicles and BDNF can promote catagen, the regression phase of hair growth.
- Catagen induction and permanent hair loss are different things, but extended catagen can cause real shedding that users may experience as hair loss even if it is technically reversible.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- BDNF does interact with hair follicle biology: Botchkarev et al. (1999) showed TrkB receptors are expressed in follicles and BDNF can promote catagen, the regression phase of hair growth.
- Catagen induction and permanent hair loss are different things, but extended catagen can cause real shedding that users may experience as hair loss even if it is technically reversible.
- No published human pharmacokinetic studies confirm whether systemic semax raises BDNF to meaningful concentrations in scalp tissue. The creator's reassurance relies on inference, not data.
- Most semax research comes from Russian clinical trials and rodent studies, with limited peer-reviewed English-language human data. Dolotov et al. (2006, Journal of Neurochemistry) is a frequently cited rodent source.
- Semax is not FDA-approved and is not a regulated drug in the United States. Anyone using it is operating without the safety net of standardized dosing, purity guarantees, or established human safety profiles.
- Semax may affect pathways beyond BDNF, including NGF and VEGF signaling, whose roles in hair cycling are not fully characterized in the published literature.
- If you notice hair changes while using any peptide compound, consult a licensed clinician rather than relying on social media content to rule out or explain the symptom.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @b.louden06 actually say?
The creator made a pretty specific claim: semax (which they called "C-Max") and other BDNF-boosting compounds will not cause hair loss. They acknowledged that some studies show BDNF applied directly to hair follicles can slow the growth phase, but argued two things: first, that slowing the growth phase is not the same as causing hair loss, and second, that you won't get high enough BDNF concentrations at the follicle level from systemic semax use to matter. The bottom line they landed on was "you really don't have to worry about it at all." That's a confident claim, and it deserves a closer look, because the reasoning is partially right but the confidence level isn't fully supported by the evidence we have.
Does the science back this up?
Partially, and with some important gaps. The BDNF-hair follicle connection is real. Research from Botchkarev et al. (1999, Journal of Investigative Dermatology) showed that BDNF and its receptor TrkB are expressed in hair follicles and that neurotrophins play a role in regulating the hair cycle. Specifically, BDNF signaling has been associated with promoting the catagen phase, which is the regression phase when active growth stops. That part of the creator's summary is broadly consistent with published work.
The second argument, that systemic semax use won't raise BDNF to concentrations high enough to affect follicles, is biologically plausible but not directly tested in any published human trial. Semax is an ACTH-derived peptide studied primarily in Russia for neuroprotection. Published research on semax in humans is limited and largely comes from Russian-language journals, with Dolotov et al. (2006, Journal of Neurochemistry) being a commonly cited source on its BDNF-elevating effects in rodents. We don't have solid human pharmacokinetic data showing exactly where BDNF goes after semax administration.
What did they get wrong (or right)?
They got the directional science right. The claim that slowing the growth phase is distinct from causing hair loss is technically accurate. Catagen induction is not the same as alopecia or follicle destruction. That distinction matters and deserves credit. The creator is not making up the BDNF-follicle relationship; it's a real area of research.
Where they overcorrected is the certainty. Saying "you really don't have to worry about it at all" is stronger than the evidence allows. Here's why:
- There are no published human trials measuring BDNF levels in scalp tissue after semax administration. The pharmacokinetic argument is inference, not data.
- Individual variation in BDNF receptor sensitivity and semax dosing patterns could change the picture for specific users.
- Prolonged catagen induction, even without follicle death, can produce noticeable shedding in practice, which many users would call hair loss even if technically temporary.
The creator's framing also skips the fact that semax may affect other pathways beyond BDNF, including NGF and VEGF signaling, whose roles in hair cycling are not fully characterized.
What should you actually know?
The honest answer is that the hair loss risk from semax is probably low based on mechanism, but it is not zero and it is not well-studied in humans. The BDNF-follicle connection is real science, not paranoia. If someone notices increased shedding while using semax, dismissing it as impossible because "you won't get concentrated levels" is not a satisfying or evidence-based response. It's speculation that happens to be plausible.
Anyone using semax should understand that this is an unregulated compound in most countries, not FDA-approved, and the human evidence base is thin. The existing studies are mostly animal models or small Russian clinical trials with limited generalizability. Anyone experiencing unexpected hair changes while using peptides should speak with a licensed clinician, not rely on social media reassurance. The catagen-versus-alopecia distinction the creator makes is legitimate, but it doesn't mean the concern is baseless or that a confident "don't worry about it" is warranted.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
B.Louden · TikTok creator
6.5K views on this video
Neuroplasticity 👑 #nootropics #brain #iq #money #semax
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about bdnf does interact with hair follicle biology: botchkarev et al.?
BDNF does interact with hair follicle biology: Botchkarev et al. (1999) showed TrkB receptors are expressed in follicles and BDNF can promote catagen, the regression phase of hair growth.
What does the video say about catagen induction?
Catagen induction and permanent hair loss are different things, but extended catagen can cause real shedding that users may experience as hair loss even if it is technically reversible.
What does the video say about no published human pharmacokinetic studies confirm whether systemic semax raises?
No published human pharmacokinetic studies confirm whether systemic semax raises BDNF to meaningful concentrations in scalp tissue. The creator's reassurance relies on inference, not data.
What does the video say about most semax research comes from russian clinical trials?
Most semax research comes from Russian clinical trials and rodent studies, with limited peer-reviewed English-language human data. Dolotov et al. (2006, Journal of Neurochemistry) is a frequently cited rodent source.
What does the video say about semax?
Semax is not FDA-approved and is not a regulated drug in the United States. Anyone using it is operating without the safety net of standardized dosing, purity guarantees, or established human safety profiles.
What does the video say about semax may affect pathways beyond bdnf, including ngf?
Semax may affect pathways beyond BDNF, including NGF and VEGF signaling, whose roles in hair cycling are not fully characterized in the published literature.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by B.Louden, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.